# Spruce Biosciences, Inc.: overview SPRB · Nasdaq · CIK 1683553 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/sprb.md) · [Financials](/companies/sprb/financials.md) · [Filings](/companies/sprb/filings.md) · [Insiders](/companies/sprb/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-097558.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Mar 9, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-097558). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.6](/filings/0001193125-25-274234.md) | [0.7 d](/filings/0001193125-26-097558.md) | [0.0](/filings/0000950170-25-064463.md) | [0.0](/filings/0000950170-25-108888.md) | [0.0](/filings/0001193125-25-274234.md) | [0.0 d](/filings/0001193125-26-097558.md) | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1562.8%)](/filings/0001193125-25-274234.md) | [(3453.9%) d](/filings/0001193125-26-097558.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | [(1440.4%)](/filings/0001193125-25-274234.md) | [(3380.1%) d](/filings/0001193125-26-097558.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(15.75)](/filings/0001193125-25-274234.md) | not reported | [(23.95)](/filings/0001193125-26-221605.md) | [(3.50)](/filings/0001193125-26-345876.md) | [(14.58)](/filings/0001193125-25-274234.md) | not reported | [(8.94)](/filings/0001193125-26-221605.md) | [(6.68)](/filings/0001193125-26-345876.md) | | Free cash flow | $m | not reported | [(20.7) d](/filings/0001193125-26-097558.md) | [(12.7)](/filings/0001193125-26-221605.md) | [(8.8) d](/filings/0001193125-26-345876.md) | not reported | not reported | [(8.7)](/filings/0001193125-26-221605.md) | [(22.3) d](/filings/0001193125-26-345876.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | [0.0](/filings/0000950170-24-032819.md) | [10.1](/filings/0000950170-25-053945.md) | [4.9](/filings/0001193125-26-097558.md) | [0.0](/filings/0001193125-26-097558.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | [(515.3%)](/filings/0000950170-25-053945.md) | [(1143.4%)](/filings/0001193125-26-097558.md) | not reported | | Net margin | % | not reported | not reported | [(475.0%)](/filings/0000950170-25-053945.md) | [(1079.9%)](/filings/0001193125-26-097558.md) | not reported | | Diluted EPS | $ per share | [(1.81)](/filings/0000950170-23-008456.md) | [(1.96)](/filings/0000950170-24-032819.md) | [(1.24)](/filings/0000950170-25-053945.md) | [(96.40)](/filings/0001193125-26-097558.md) | [(50.83)](/filings/0001193125-26-097558.md) | | Free cash flow | $m | [(36.0)](/filings/0000950170-23-008456.md) | [(41.7)](/filings/0000950170-24-032819.md) | [(33.3)](/filings/0000950170-25-053945.md) | [(56.0)](/filings/0001193125-26-097558.md) | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sprb/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [AIGH Capital Management LLC](/funds/1835943.md) | 2026-06-30 | $13.5m | 250,000 | | New +250,000 | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $10.8m | 200,000 | | New +200,000 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $10.1m | 187,836 | | Added +170,898 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $8.7m | 160,981 | | Added +49,093 | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $6.6m | 121,356 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $6.4m | 119,331 | | Added +100,994 | | [Alyeska Investment Group, L.P.](/funds/1453072.md) | 2026-06-30 | $4.4m | 81,671 | | Added +30,000 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $3.8m | 70,548 | | Added +57,659 | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $3.7m | 67,717 | | Added +9,117 | | [Cable Car Capital, LP](/funds/1699575.md) | 2026-06-30 | $3.2m | 60,000 | | New +60,000 | ## Recent filings [All 365 filings](/companies/sprb/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-12 | 09:10 ET | [10-Q](/filings/0001193125-26-345876.md) | Quarterly report, period 2026-06-30 | 0001193125-26-345876 | | 2026-08-12 | 09:05 ET | [8-K](/filings/0001193125-26-345874.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-345874 | | 2026-07-27 | 08:05 ET | [8-K](/filings/0001193125-26-316928.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-316928 | | 2026-05-26 | 16:02 ET | [8-K](/filings/0001193125-26-239230.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-239230 | | 2026-05-13 | 16:06 ET | [10-Q](/filings/0001193125-26-221605.md) | Quarterly report, period 2026-03-31 | 0001193125-26-221605 | | 2026-05-13 | 08:05 ET | [8-K](/filings/0001193125-26-220648.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-220648 | | 2026-04-22 | 17:50 ET | [8-K](/filings/0001193125-26-167332.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-167332 | | 2026-04-09 | 17:02 ET | [DEF 14A](/filings/0001193125-26-149821.md) | Proxy statement, period 2026-04-09 | 0001193125-26-149821 | | 2026-03-20 | 17:04 ET | [8-K](/filings/0001193125-26-117888.md) | 1.02 Termination of a material agreement | 0001193125-26-117888 | | 2026-03-09 | 07:23 ET | [8-K](/filings/0001193125-26-097561.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-097561 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-097558.md), filed Mar 9, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1683553 - Tickers: SPRB - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.